Novo Nordisk's (NVO) Victoza Returns More Promising Results Than Lilly's (LLY)/Amylin's (AMLN) Byetta
.jpg)
Up)
CNBC's Mike Huckman is reporting that a study comparing Novo Nordisk's (NYSE: NVO) Victoza and Eli Lilly's (NYSE: LLY)/Amylin's (Nasdaq: AMLN) Byetta returned better results for the Novo drug.
Novo's Victoza lowered patients blood sugar levels by 1.1%. During the study, 54% of patients taking Victoza reached their blood sugar level goal, while only 43% of patients taking Byetta achieved their goal. Also, patients taking Novo's product lost 7 pounds, compared to Byetta's 6.4 pounds lost.
Novo's Victoza lowered patients blood sugar levels by 1.1%. During the study, 54% of patients taking Victoza reached their blood sugar level goal, while only 43% of patients taking Byetta achieved their goal. Also, patients taking Novo's product lost 7 pounds, compared to Byetta's 6.4 pounds lost.
You May Also Be Interested In
- Icahn's Letter to the Chesapeake (CHK) Board: Says Directors Failed to Oversee, Hold Management Accountable
- Mattress Stocks Zip Higher on Positive Comments (TPX) (SCSS) (ZZ) (MFRM)
- EUR/CHF Spike Remains Mystery
Create E-mail Alert Related Categories
Corporate News, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
